Sun Pharmaceutical rises on securing USFDA’s nod for review of ILUMYA
Sun Pharmaceutical Industries is currently trading at Rs. 1797.25, up by 14.70 points or 0.82% from its previous closing of Rs. 1782.55 on the BSE.
The scrip opened at Rs. 1792.00 and has touched a high and low of Rs. 1799.70 and Rs. 1781.20 respectively. So far 5474 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1850.95 on 02-May-2025 and a 52 week low of Rs. 1547.25 on 26-Sep-2025.
Last one week high and low of the scrip stood at Rs. 1842.50 and Rs. 1768.55 respectively. The current market cap of the company is Rs. 430092.79 crore.
The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 36.93% and 8.58% respectively.
Sun Pharmaceutical Industries has secured United States Food and Drug Administration’s (FDA) acceptance for review of the supplemental Biologics License Application (sBLA) for ILUMYA for the treatment of adults with active psoriatic arthritis. The FDA regulatory action date for this sBLA is expected by October 29, 2026.
If approved, this would mark a new indication for ILUMYA following its US FDA approval in 2018 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Scalp and nail plaque psoriasis sBLAs were approved in April 2024, and December 2025, respectively. ILUMYA has also received marketing authorization from over 55 worldwide health authorities since its original approval, including in India, Japan, the European Union, China, Australia and Canada.
The sBLA is based on the results from the INSPIRE-1 and INSPIRE-2 Phase 3 clinical studies evaluating the efficacy and safety of ILUMYA in adult patients with active psoriatic arthritis. Top-line findings from these studies were reported in July 2025.
